Shares of Generex Biotechnology Co. (OTCMKTS:GNBT – Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.00. Generex Biotechnology shares last traded at $0.00, with a volume of 0 shares.
Generex Biotechnology Price Performance
Generex Biotechnology Company Profile
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer.
Featured Articles
- Five stocks we like better than Generex Biotechnology
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- What Makes a Stock a Good Dividend Stock?
- Applied Materials Market Capitulates: Now is the Time to Buy
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Generex Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generex Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
